Chimerix (NASDAQ:CMRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX) in a research report sent to investors on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on CMRX. Jefferies Financial Group reissued a “hold” rating and issued a $8.50 target price (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush restated a “neutral” rating and set a $8.55 price objective (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Stock Up 0.1 %

Shares of CMRX opened at $8.47 on Friday. The stock has a market cap of $761.76 million, a P/E ratio of -9.01 and a beta of 0.32. The business’s 50 day moving average price is $4.94 and its 200-day moving average price is $2.64. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.48.

Insider Activity

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 20,760 shares of company stock valued at $91,175 over the last three months. Insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

Institutional investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 138,098 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after acquiring an additional 496,823 shares in the last quarter. Stoneridge Investment Partners LLC raised its stake in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 8,134 shares during the period. Peapod Lane Capital LLC bought a new stake in Chimerix during the 4th quarter worth approximately $2,626,000. Finally, Valeo Financial Advisors LLC lifted its holdings in Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 64,420 shares in the last quarter. 45.42% of the stock is owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.